The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research Report: Human NENF / Neudesin (UniProt Q9UMX5)

0) Target verification (critical identity check)

Human NENF encodes neudesin (neuron-derived neurotrophic factor), a secreted MAPR-family protein with a cytochrome b5-like heme/steroid-binding domain, matching UniProt accession Q9UMX5 (cahill2017theevolutionaryappearance pages 13-14, wang2024identificationofthe pages 1-2). Recent human cancer work also uses the same identity/aliases (NENF = neudesin = GIG47) and describes a 172-aa secreted protein with a cytochrome b5-like heme/steroid-binding domain, consistent with UniProt (wang2024identificationofthe pages 1-2, ohta2015neudesinasa pages 1-2).

1) Key concepts and definitions (current understanding)

1.1 Gene/protein nomenclature and aliases

Neudesin is also referred to as NENF and has been described in the cancer literature under the alias GIG47 (wang2024identificationofthe pages 1-2, ohta2015neudesinasa pages 2-4). A 2015 review summarizes this nomenclature explicitly (neudesin ≈ NENF ≈ GIG47) (ohta2015neudesinasa pages 1-2).

1.2 Protein class: MAPR (membrane-associated progesterone receptor) family

Neudesin is part of the MAPR protein family, which includes PGRMC1, PGRMC2, neudesin (NENF), and neuferricin (CYB5D2); MAPR proteins share a CYB5/cytochrome b5-like heme/steroid-binding domain (kimura2013neurotrophiceffectsof pages 2-4, ohta2015neudesinasa pages 2-4). A pharmacology mini-review emphasizes that MAPRs are small proteins with a similar non-covalent heme-binding domain related to cytochrome b5, and that neudesin is among the four MAPR proteins (ohta2015neudesinasa pages 2-4).

1.3 Localization: secreted/extracellular protein

Primary and review sources describe neudesin as a secreted protein (kimura2008neurotrophicactivityof pages 3-4, kimura2013neurotrophiceffectsof pages 2-4). In the oncology structural paper, GIG47/neudesin is described as a secreted protein and reported to be found mainly in extracellular supernatant (ohta2015neudesinasa pages 2-4).

1.4 Key domain and biochemical activity: heme binding enables function

A foundational mechanistic study established neudesin as an extracellular heme-binding protein whose neurotrophic activity depends on heme binding to the cytochrome b5-like heme/steroid-binding domain (kimura2008neurotrophicactivityof pages 3-4). Reviews further specify conserved residues (including conserved tyrosines) required for heme binding and activity (kimura2013neurotrophiceffectsof pages 2-4, ohta2015neudesinasa pages 1-2).

Interpretation for functional annotation: NENF is best conceptualized as a secreted signaling protein whose activity is modulated by heme (and potentially steroid-like ligands), rather than as a classical enzyme catalyzing a specific chemical reaction (kimura2008neurotrophicactivityof pages 3-4, kimura2013neurotrophiceffectsof pages 2-4).

2) Mechanisms and signaling pathways

2.1 MAPK/ERK and PI3K/AKT signaling

Neudesin activates MAPK/ERK and PI3K/AKT signaling in multiple contexts, including neuronal systems; this is synthesized in authoritative reviews (kimura2013neurotrophiceffectsof pages 2-4, ohta2015neudesinasa pages 1-2). In the 2008 JBC mechanistic paper, ERK1/2 and Akt phosphorylation were directly assayed by Western blot as part of defining neudesin signaling readouts (kimura2008neurotrophicactivityof pages 3-4).

2.2 Evidence for GPCR-linked signaling (Gi/Go vs Gs/cAMP)

A detailed review proposes that neudesin may signal through G protein-coupled receptor (GPCR) mechanisms, based on pertussis toxin (PTX) sensitivity of ERK1/2 phosphorylation in some systems (suggesting Gi/Go coupling), while in neural precursor cells neudesin increased cAMP and signaled via PKA and PI3K (suggesting Gs-linked signaling), and notes that a definitive receptor has not been identified (kimura2013neurotrophiceffectsof pages 2-4, ohta2015neudesinasa pages 2-4).

2.3 Heme dependence as a functional “switch”

A CNS-focused review reports that a neudesin–hemin complex can have stronger neuroprotective/pro-proliferative activity than neudesin alone, consistent with heme acting as an activity-modulating cofactor/ligand (kimura2013neurotrophiceffectsof pages 2-4). This aligns with the original mechanistic conclusion that heme binding is required for neurotrophic activity (kimura2008neurotrophicactivityof pages 3-4).

3) Core biological functions (functional annotation)

3.1 Neurotrophic and neurogenesis roles

Neudesin is described as a neuron-derived neurotrophic factor involved in neuronal differentiation and survival, abundantly expressed in the CNS (kimura2013neurotrophiceffectsof pages 1-2). Reviews summarize experimental evidence that neudesin promotes neuronal differentiation and survival via MAPK/PI3K signaling (kimura2013neurotrophiceffectsof pages 2-4, kimura2013neurotrophiceffectsof pages 1-2).

3.2 Energy balance and metabolism

In vivo: Neudesin knockout mice are reported to be resistant to high-fat diet-induced obesity, with increased sympathetic activity, increased energy expenditure, increased thermogenesis/fatty-acid oxidation in brown adipose tissue, and increased lipolysis in white adipose tissue (ohta2015deletionofthe pages 1-2). A 2015 integrative review frames neudesin as a negative regulator of energy expenditure and a multi-functional secreted factor in energy metabolism (ohta2015neudesinasa pages 1-2).

Central appetite regulation: Intracerebroventricular administration of recombinant neudesin reduced food intake and body weight and altered hypothalamic melanocortin-related readouts; this is summarized in reviews (kimura2013neurotrophiceffectsof pages 2-4, ohta2015neudesinasa pages 2-4).

3.3 Adipogenesis

Neudesin has been reported to modulate adipogenesis in vitro (3T3-L1), with mechanistic links to the MAPK cascade summarized in MAPR-family literature (cahill2017theevolutionaryappearance pages 13-14).

3.4 Tumorigenesis and cancer progression

A structural/cancer biology study (GIG47) showed overexpression in multiple tumors and reported that ectopic expression promoted invasiveness and tumorigenicity, with tumorigenesis potentially mediated by MAPK and PI3K pathways; it also provided a high-resolution structural model that includes a potential heme/steroid-binding pocket (ohta2015neudesinasa pages 2-4). Recent TNBC work provides strong evidence for a pro-metastatic role (see Section 4) (wang2024identificationofthe pages 9-13).

4) Recent developments and latest research (prioritizing 2023–2024)

4.1 2024: Triple-negative breast cancer (TNBC) metastasis-associated subclusters and EMT

A 2024 study integrating single-cell expression profiles of primary and metastatic TNBC identified NENF as a metastasis-related gene, with multiple lines of validation (wang2024identificationofthe pages 1-2, wang2024identificationofthe pages 9-13). Key quantitative results include:

• Copy-number amplification in TCGA-TNBC: 88/114 (77.2%) amplified (wang2024identificationofthe pages 9-13, wang2024identificationofthe media e32e9d32).
• Tissue validation: RT-qPCR in 30 paired TNBC vs adjacent samples and IHC in 20 paired samples showed increased NENF in tumors (wang2024identificationofthe pages 9-13).
• Functional perturbation: NENF knockdown reduced invasion/migration and shifted EMT markers (↑E-cadherin, ↓N-cadherin/Vimentin), indicating NENF promotes EMT-like programs required for invasiveness (wang2024identificationofthe pages 9-13).
• Clinical implication: Higher NENF expression associated with poorer overall and recurrence-free survival; survival plots and IHC quantification are shown in Figure 6 (wang2024identificationofthe media e32e9d32).

This work also nominated candidate compounds for “high-NENF” patients via computational resources (Connectivity Map) and suggested differential response to immune checkpoint inhibitors via TIDE analysis (wang2024identificationofthe pages 9-13).

4.2 2023: Single-cell RNA-seq implicates NENF in immune-cell metabolic dysregulation in pediatric aplastic anemia

A 2023 scRNA-seq study of peripheral blood from 5 children with aplastic anemia and 3 healthy donors identified NENF among key differentially expressed genes tied to abnormal metabolic processes and reported NENF expression is significantly higher in AA (zhou2023singlecellrnasequencing pages 1-2, zhou2023singlecellrnasequencing pages 2-4). The study also reported enrichment of lysine degradation dysregulation (q = 0.0051) and described T- and NK-cell metabolic pathway shifts (zhou2023singlecellrnasequencing pages 2-4, zhou2023singlecellrnasequencing pages 1-2). While not a mechanistic dissection of NENF, it is recent evidence placing NENF in immune-disease single-cell signatures.

4.3 2024: Reproductive endocrinology association—PCOS serum neudesin

A 2024 case-control study measured serum neudesin in 90 women (60 PCOS, 30 controls) using sandwich ELISA and found significantly lower neudesin in PCOS: 0.75 ± 0.05 ng/mL vs 2.86 ± 0.06 ng/mL (P<0.05) (salih2024estimationthelevel pages 1-4). Subgroup quantitative findings included:

• By age (PCOS): <20 years 0.24 ± 0.019 (n=15); 20–29 years 0.658 ± 0.042 (n=25); 30–39 years 1.25 ± 0.028 ng/mL (n=20) (salih2024estimationthelevel pages 4-7).
• By BMI (PCOS): obese 0.43 ± 0.04 (n=35) vs overweight 1.2 ± 0.03 ng/mL (n=25) (salih2024estimationthelevel pages 4-7).
• By WHR (PCOS): high WHR 0.5 ± 0.04 (n=40) vs moderate WHR 1.25 ± 0.03 ng/mL (n=20) (salih2024estimationthelevel pages 4-7).

The authors propose neudesin as a potential prognostic marker for PCOS, though this conclusion should be regarded as preliminary pending independent replication and evaluation of diagnostic performance (salih2024estimationthelevel pages 1-4).

5) Current applications and real-world implementations

5.1 Circulating biomarker research in metabolic and reproductive disorders

• Obesity/T2DM intervention biomarker: A 2019 clinical study measured serum neudesin in multiple cohorts and found it changed with acute fasting and with a bariatric endoscopic device intervention (DJBL), with statistically significant changes (P=0.001) (kratochvilova2019<p>neudesininobesity pages 1-2). This indicates feasibility as a dynamic circulating marker responsive to energy-balance interventions.
• PCOS biomarker: The 2024 PCOS study proposes serum neudesin as a prognostic marker for early PCOS detection and reports strong group differences (salih2024estimationthelevel pages 1-4, salih2024estimationthelevel pages 4-7).

5.2 Oncology biomarker/target prioritization

• TNBC: NENF is proposed as a prognostic biomarker and potential therapeutic target in TNBC, supported by amplification/overexpression, survival associations, and functional invasion assays (wang2024identificationofthe pages 9-13, wang2024identificationofthe media e32e9d32).
• Knowledgebase integration: Open Targets links NENF to disease areas including obesity, TNBC, ovarian dysfunction, and brain neoplasm, enabling hypothesis generation and target prioritization workflows in drug discovery contexts (OpenTargets Search: -NENF).

6) Expert opinions and analysis (authoritative interpretations)

6.1 Neudesin as a heme/steroid-binding secreted signaling protein

Authoritative reviews converge on a model where neudesin is a secreted MAPR-family protein whose biological effects are mediated by intracellular signaling cascades (MAPK/ERK, PI3K/AKT) and modulated by binding to heme (kimura2013neurotrophiceffectsof pages 2-4, ohta2015neudesinasa pages 1-2). This framing helps reconcile its pleiotropic roles across neural development, energy homeostasis, and tumorigenesis.

6.2 Receptor uncertainty remains a key knowledge gap

Despite GPCR-linked pharmacological features (e.g., PTX sensitivity in some contexts), reviews emphasize that no definitive receptor has been identified, making receptor identification a major open problem for the field and a bottleneck for therapeutic targeting (kimura2013neurotrophiceffectsof pages 2-4).

6.3 Translational caution

While multiple studies propose neudesin as a biomarker (PCOS, obesity/T2DM interventions, TNBC prognosis), evidence remains heterogeneous across conditions and methodologies; application as a clinical biomarker requires prospective validation, standardized assays, and performance metrics (AUC, sensitivity/specificity) that are not yet consistently available in the retrieved corpus (salih2024estimationthelevel pages 1-4, wang2024identificationofthe pages 9-13, kratochvilova2019<p>neudesininobesity pages 1-2).

7) Statistics and data highlights (selected)

• TNBC amplification: NENF amplified in 88/114 (77.2%) TCGA-TNBC cases (wang2024identificationofthe pages 9-13, wang2024identificationofthe media e32e9d32).
• TNBC validation sample sizes: 30 paired tumor/adjacent samples (RT-qPCR) and 20 paired samples (IHC) (wang2024identificationofthe pages 9-13).
• PCOS serum neudesin: 0.75 ± 0.05 ng/mL (PCOS) vs 2.86 ± 0.06 ng/mL (controls), n=60 vs 30 (salih2024estimationthelevel pages 1-4).
• Obesity/T2DM interventions: DJBL increased serum neudesin (e.g., 1.77 ± 0.86 → 2.28 ± 1.27 ng/mL, P=0.001); 72h fasting decreased it (1.74 ± 0.54 → 1.46 ± 0.48 ng/mL, P=0.001) (kratochvilova2019<p>neudesininobesity pages 1-2).
• Aplastic anemia scRNA-seq: cohort 5 AA vs 3 controls; lysine degradation dysregulation enriched (q=0.0051) (zhou2023singlecellrnasequencing pages 2-4, zhou2023singlecellrnasequencing pages 1-2).

Evidence synthesis table

The following table consolidates the key evidence, emphasizing recent 2023–2024 sources and foundational mechanistic work with publication dates and URLs.

Table: This table summarizes core functional-annotation evidence for human NENF/neudesin (UniProt Q9UMX5), combining foundational mechanistic papers with recent 2023-2024 disease and biomarker studies. It highlights localization, heme dependence, signaling, physiological roles, and translational associations with quantitative details where available.

8) Summary for functional annotation

Neudesin (NENF; UniProt Q9UMX5) is best annotated as a secreted/extracellular MAPR-family heme-binding signaling protein whose activity depends on heme binding to a cytochrome b5-like heme/steroid-binding domain and which activates MAPK/ERK and PI3K/AKT signaling (kimura2008neurotrophicactivityof pages 3-4, kimura2013neurotrophiceffectsof pages 2-4). Its strongest experimentally supported physiological roles include neurotrophic/neurogenic functions and regulation of energy expenditure/sympathetic tone (kimura2013neurotrophiceffectsof pages 2-4, ohta2015deletionofthe pages 1-2). Recent translational research links NENF to TNBC metastasis and EMT, with high amplification frequency and validation in patient tissues and cell models (wang2024identificationofthe pages 9-13, wang2024identificationofthe media e32e9d32). Human circulating neudesin levels are being explored as a biomarker in obesity/T2DM interventions and PCOS, though clinical utility remains to be validated (kratochvilova2019<p>neudesininobesity pages 1-2, salih2024estimationthelevel pages 1-4).

References

1. (cahill2017theevolutionaryappearance pages 13-14): Michael A. Cahill. The evolutionary appearance of signaling motifs in pgrmc1. Bioscience trends, 11 2:179-192, Feb 2017. URL: https://doi.org/10.5582/bst.2017.01009, doi:10.5582/bst.2017.01009. This article has 34 citations and is from a peer-reviewed journal.

2. (wang2024identificationofthe pages 1-2): Guixin Wang, Cangchang Shi, Long He, Yingxi Li, Wenbin Song, Zhaohui Chen, Zhaoyi Liu, Yizeng Wang, Xianghui He, Yue Yu, Yao Tian, and Xin Wang. Identification of the tumor metastasis-related tumor subgroups overexpressed nenf in triple-negative breast cancer by single-cell transcriptomics. Cancer Cell International, Sep 2024. URL: https://doi.org/10.1186/s12935-024-03505-z, doi:10.1186/s12935-024-03505-z. This article has 24 citations and is from a peer-reviewed journal.

3. (ohta2015neudesinasa pages 1-2): Hiroya Ohta, Ikuo Kimura, Morichika Konishi, and Nobuyuki Itoh. Neudesin as a unique secreted protein with multi-functional roles in neural functions, energy metabolism, and tumorigenesis. Frontiers in Molecular Biosciences, May 2015. URL: https://doi.org/10.3389/fmolb.2015.00024, doi:10.3389/fmolb.2015.00024. This article has 48 citations.

4. (ohta2015neudesinasa pages 2-4): Hiroya Ohta, Ikuo Kimura, Morichika Konishi, and Nobuyuki Itoh. Neudesin as a unique secreted protein with multi-functional roles in neural functions, energy metabolism, and tumorigenesis. Frontiers in Molecular Biosciences, May 2015. URL: https://doi.org/10.3389/fmolb.2015.00024, doi:10.3389/fmolb.2015.00024. This article has 48 citations.

5. (kimura2013neurotrophiceffectsof pages 2-4): Ikuo Kimura, Yoshiaki Nakayama, Ying Zhao, Morichika Konishi, and Nobuyuki Itoh. Neurotrophic effects of neudesin in the central nervous system. Frontiers in Neuroscience, May 2013. URL: https://doi.org/10.3389/fnins.2013.00111, doi:10.3389/fnins.2013.00111. This article has 40 citations and is from a peer-reviewed journal.

6. (kimura2008neurotrophicactivityof pages 3-4): Ikuo Kimura, Yoshiaki Nakayama, Hajime Yamauchi, Morichika Konishi, Ayumi Miyake, Masahiro Mori, Mitsuhiro Ohta, Nobuyuki Itoh, and Masafumi Fujimoto. Neurotrophic activity of neudesin, a novel extracellular heme-binding protein, is dependent on the binding of heme to its cytochrome b5-like heme/steroid-binding domain*. Journal of Biological Chemistry, 283:4323-4331, Feb 2008. URL: https://doi.org/10.1074/jbc.m706679200, doi:10.1074/jbc.m706679200. This article has 79 citations and is from a domain leading peer-reviewed journal.

7. (kimura2013neurotrophiceffectsof pages 1-2): Ikuo Kimura, Yoshiaki Nakayama, Ying Zhao, Morichika Konishi, and Nobuyuki Itoh. Neurotrophic effects of neudesin in the central nervous system. Frontiers in Neuroscience, May 2013. URL: https://doi.org/10.3389/fnins.2013.00111, doi:10.3389/fnins.2013.00111. This article has 40 citations and is from a peer-reviewed journal.

8. (ohta2015deletionofthe pages 1-2): Hiroya Ohta, Morichika Konishi, Yusuke Kobayashi, Atsuki Kashio, Takayuki Mochiyama, Shigenobu Matsumura, Kazuo Inoue, Tohru Fushiki, Kazuwa Nakao, Ikuo Kimura, and Nobuyuki Itoh. Deletion of the neurotrophic factor neudesin prevents diet-induced obesity by increased sympathetic activity. Scientific Reports, May 2015. URL: https://doi.org/10.1038/srep10049, doi:10.1038/srep10049. This article has 42 citations and is from a peer-reviewed journal.

9. (wang2024identificationofthe pages 9-13): Guixin Wang, Cangchang Shi, Long He, Yingxi Li, Wenbin Song, Zhaohui Chen, Zhaoyi Liu, Yizeng Wang, Xianghui He, Yue Yu, Yao Tian, and Xin Wang. Identification of the tumor metastasis-related tumor subgroups overexpressed nenf in triple-negative breast cancer by single-cell transcriptomics. Cancer Cell International, Sep 2024. URL: https://doi.org/10.1186/s12935-024-03505-z, doi:10.1186/s12935-024-03505-z. This article has 24 citations and is from a peer-reviewed journal.

10. (wang2024identificationofthe media e32e9d32): Guixin Wang, Cangchang Shi, Long He, Yingxi Li, Wenbin Song, Zhaohui Chen, Zhaoyi Liu, Yizeng Wang, Xianghui He, Yue Yu, Yao Tian, and Xin Wang. Identification of the tumor metastasis-related tumor subgroups overexpressed nenf in triple-negative breast cancer by single-cell transcriptomics. Cancer Cell International, Sep 2024. URL: https://doi.org/10.1186/s12935-024-03505-z, doi:10.1186/s12935-024-03505-z. This article has 24 citations and is from a peer-reviewed journal.

11. (zhou2023singlecellrnasequencing pages 1-2): Qin C Zhou, Lifeng Huang, Yong Liu, Junbin Huang, Lu Wen, Jing Yang, Jintang Liang, Yuxiang Chen, and Chun Chen. Single-cell rna sequencing depicts metabolic changes in children with aplastic anemia. Frontiers in Oncology, Mar 2023. URL: https://doi.org/10.3389/fonc.2023.1075408, doi:10.3389/fonc.2023.1075408. This article has 5 citations.

12. (zhou2023singlecellrnasequencing pages 2-4): Qin C Zhou, Lifeng Huang, Yong Liu, Junbin Huang, Lu Wen, Jing Yang, Jintang Liang, Yuxiang Chen, and Chun Chen. Single-cell rna sequencing depicts metabolic changes in children with aplastic anemia. Frontiers in Oncology, Mar 2023. URL: https://doi.org/10.3389/fonc.2023.1075408, doi:10.3389/fonc.2023.1075408. This article has 5 citations.

13. (salih2024estimationthelevel pages 1-4): Saba Ibrahim Salih and Arshad Noori Al-Dujaili. Estimation the level of neudesin in polycystic ovarian syndrome patients. BIO Web of Conferences, 108:04012, Jan 2024. URL: https://doi.org/10.1051/bioconf/202410804012, doi:10.1051/bioconf/202410804012. This article has 1 citations.

14. (salih2024estimationthelevel pages 4-7): Saba Ibrahim Salih and Arshad Noori Al-Dujaili. Estimation the level of neudesin in polycystic ovarian syndrome patients. BIO Web of Conferences, 108:04012, Jan 2024. URL: https://doi.org/10.1051/bioconf/202410804012, doi:10.1051/bioconf/202410804012. This article has 1 citations.

15. (kratochvilova2019<p>neudesininobesity pages 1-2): Helena Kratochvilova, Zdenka Lacinova, Jana Klouckova, Petra Kavalkova, Anna Cinkajzlova, Pavel Trachta, Jarmila Krizova, Marek Benes, Karin Dolezalova, Martin Fried, Zuzana Vlasakova, Terezie Pelikanova, Julius Spicak, Milos Mraz, and Martin Haluzik. <p>neudesin in obesity and type 2 diabetes mellitus: the effect of acute fasting and weight reducing interventions</p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Volume 12:423-430, Mar 2019. URL: https://doi.org/10.2147/dmso.s193259, doi:10.2147/dmso.s193259. This article has 14 citations.

16. (OpenTargets Search: -NENF): Open Targets Query (-NENF, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

17. (ohta2015neudesinasa pages 4-5): Hiroya Ohta, Ikuo Kimura, Morichika Konishi, and Nobuyuki Itoh. Neudesin as a unique secreted protein with multi-functional roles in neural functions, energy metabolism, and tumorigenesis. Frontiers in Molecular Biosciences, May 2015. URL: https://doi.org/10.3389/fmolb.2015.00024, doi:10.3389/fmolb.2015.00024. This article has 48 citations.

Artifacts

• Edison artifact artifact-00
  

Citations

1. ohta2015neudesinasa pages 1-2
2. ohta2015neudesinasa pages 2-4
3. kimura2008neurotrophicactivityof pages 3-4
4. kimura2013neurotrophiceffectsof pages 2-4
5. kimura2013neurotrophiceffectsof pages 1-2
6. ohta2015deletionofthe pages 1-2
7. cahill2017theevolutionaryappearance pages 13-14
8. wang2024identificationofthe pages 9-13
9. salih2024estimationthelevel pages 1-4
10. salih2024estimationthelevel pages 4-7
11. wang2024identificationofthe pages 1-2
12. zhou2023singlecellrnasequencing pages 1-2
13. zhou2023singlecellrnasequencing pages 2-4
14. ohta2015neudesinasa pages 4-5
15. https://doi.org/10.1074/jbc.m706679200
16. https://doi.org/10.3389/fnins.2013.00111
17. https://doi.org/10.1038/srep10049
18. https://doi.org/10.3389/fmolb.2015.00024
19. https://doi.org/10.1186/1471-2407-12-274
20. https://doi.org/10.2147/DMSO.S193259
21. https://doi.org/10.3389/fonc.2023.1075408
22. https://doi.org/10.1051/bioconf/202410804012
23. https://doi.org/10.1186/s12935-024-03505-z
24. https://platform.opentargets.org/target/ENSG00000117691
25. https://doi.org/10.5582/bst.2017.01009,
26. https://doi.org/10.1186/s12935-024-03505-z,
27. https://doi.org/10.3389/fmolb.2015.00024,
28. https://doi.org/10.3389/fnins.2013.00111,
29. https://doi.org/10.1074/jbc.m706679200,
30. https://doi.org/10.1038/srep10049,
31. https://doi.org/10.3389/fonc.2023.1075408,
32. https://doi.org/10.1051/bioconf/202410804012,
33. https://doi.org/10.2147/dmso.s193259,

Comprehensive Research Report on NENF (Neudesin): Structure, Function, and Biological Roles

Gene Symbol: NENF (Neuron-Derived Neurotrophic Factor; also known as Neudesin, GIG47)
UniProt Accession: Q9UMX5
Organism: Homo sapiens (Human)
Protein Family: Membrane-Associated Progesterone Receptor (MAPR) Family; Cytochrome b5 Family
Gene Location: Human genome (specific chromosomal location confirmed through UniProt database)

Neudesin, officially designated as the protein product of the NENF gene, represents a unique secreted neurotrophic factor with remarkable evolutionary conservation across vertebrates and an increasingly recognized multifunctional role spanning neural development, energy homeostasis, anxiety regulation, and tumorigenesis. Originally identified as a secreted protein with neurotrophic activity in neurons, neudesin has since emerged as one of the most pleiotropic members of the cytochrome b5-related protein family, with cellular effects extending far beyond classical neurotrophic signaling paradigms. This report synthesizes contemporary molecular and cellular research to establish neudesin's precise biochemical functions, delineate its role in specific biological pathways, and examine evidence for its therapeutic potential in obesity, anxiety disorders, and cancer treatment.

Molecular Structure, Evolutionary Conservation, and Biochemical Characterization

Neudesin is a secreted protein comprising 172 amino acids in humans that exhibits remarkably high sequence conservation across vertebrate species, including mammals from humans to mice, birds, amphibians, and fish, indicating significant evolutionary pressure to maintain its structure and function[1][19][46]. The protein contains a distinctive N-terminal signal peptide characteristic of secreted proteins, which directs the nascent polypeptide chain into the endoplasmic reticulum for signal peptide cleavage and subsequent secretory pathway trafficking[1][46]. The most critical structural feature of neudesin is its conserved cytochrome b5-like heme/steroid-binding domain, which occupies the central portion of the protein and is essential for its biological activity[1][7][9]. This heme-binding domain is positioned within an α2-β4-α3 topology and creates a hydrophobic binding pocket between the α2 and α3 helices[9][15]. Nuclear magnetic resonance structural analysis has revealed that neudesin possesses an overall architecture composed of four α-helices and six β-strands arranged in a β1-α1-β2-β3-α2-β4-α3-α4-β5-β6 topology[9][15][26].

The heme-binding functionality of neudesin is mediated by two conserved tyrosine residues, specifically tyrosine-82 and tyrosine-88 in the human sequence, which form the critical iron-binding site within the hydrophobic pocket[9][15][25][26]. These tyrosine residues are absolutely essential for heme binding, as demonstrated by studies employing recombinant mutant neudesin lacking the heme-binding domain (neudesinΔHBD), which completely loses the capacity to bind hemin[7][36]. The binding of iron(III)-protoporphyrin IX (hemin) to neudesin significantly enhances its neurotrophic activity, with neudesin-hemin complexes demonstrating substantially greater biological potency than neudesin alone in both primary cultured neurons and undifferentiated neural cell lines[7][36][44]. Interestingly, the neurotrophic activity of neudesin is enhanced specifically by Fe(III)-protoporphyrin IX but not by Fe(II)-protoporphyrin IX or protoporphyrin IX alone, indicating a strict requirement for the oxidation state of the iron atom[7][36]. This dependence on iron oxidation state suggests that neudesin may serve a function related to redox sensing or oxidative stress modulation within the extracellular microenvironment.

From an evolutionary perspective, neudesin represents a unique member of the membrane-associated progesterone receptor (MAPR) family, which includes four characterized members: progesterone receptor membrane component 1 (PGRMC1), PGRMC2, neudesin, and neuferricin[4][9][26][47]. Although all four proteins share the characteristic cytochrome b5-like heme/steroid-binding domain, neudesin occupies a distinct evolutionary position within this family[9][26][57]. Specifically, PGRMC1 and PGRMC2 were generated from a common ancestral gene and possess two conserved introns in their coding regions with conserved positions, whereas neudesin contains non-conserved introns and is not evolutionarily related to the PGRMC1/PGRMC2 lineage[26][57]. Furthermore, PGRMC1 and PGRMC2 are transmembrane proteins primarily localized to the endoplasmic reticulum, while neudesin, like neuferricin, is a secreted protein that functions in the extracellular milieu[26][47][57]. This structural and evolutionary distinction suggests that neudesin evolved independently to serve as an extracellular ligand for G-protein-coupled receptors rather than functioning as a membrane-tethered receptor itself.

Expression Patterns and Cellular Localization During Development

The temporal and spatial expression patterns of neudesin provide important clues regarding its developmental functions and physiological roles[1][19][46][52]. Neudesin expression begins during early embryonic development, specifically at approximately embryonic day 12.5 (E12.5) in mice, as demonstrated by quantitative real-time PCR analysis of neural precursor cells[52]. During the subsequent embryonic period, neudesin expression increases progressively in neural tissues in an inverse correlation with nestin, a marker of actively dividing neural precursor cells, and in direct correlation with microtubule-associated protein 2 (MAP-2), a marker of mature differentiated neurons[52]. This temporal expression pattern strongly suggests that neudesin plays a critical role in the transition from neural precursor proliferation to neuronal differentiation during brain development. During embryonic stages, neudesin is preferentially expressed in the brain and spinal cord, with particularly high expression in the cortical preplate, a transient embryonic structure that participates in cortical formation[1][19][37][46]. After birth, the expression pattern of neudesin becomes more widespread, with detection of neudesin mRNA and protein in various peripheral tissues including adipose tissue (both white and brown), heart, lung, kidney, and other organs[1][3][19][20][46]. In the adult brain, neudesin continues to be expressed in neurons but with lower overall levels compared to embryonic expression[1][19]. Within the adult brain, neudesin is prominently expressed in the hypothalamus, particularly in neurons involved in appetite regulation, and in the hippocampus, specifically in dentate gyrus granule cells of the ventral hippocampus, which is part of the neural circuitry mediating anxiety-related behaviors[1][3][4][19].

The intracellular localization of neudesin reflects its function as a secreted protein. As a secreted protein with a signal peptide, neudesin is synthesized on membrane-bound ribosomes and undergoes co-translational translocation into the rough endoplasmic reticulum[1][19][46]. Following signal peptide cleavage, neudesin transit through the classical secretory pathway: from the endoplasmic reticulum to the Golgi apparatus for post-translational modification and packaging into secretory vesicles, which subsequently fuse with the plasma membrane to release neudesin into the extracellular space[46]. Once secreted, neudesin is expected to act on neighboring cells expressing the appropriate neudesin receptors, though the specific receptors remain unidentified[1][4][9][15][19].

Molecular Mechanisms of Signal Transduction

Neudesin exerts its biological effects through activation of specific intracellular signaling pathways that have been extensively characterized through studies employing recombinant neudesin, pertussis toxin, pathway-specific inhibitors, and molecular knockdown approaches. The primary mechanism through which neudesin activates intracellular signaling involves the mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol 3-kinase (PI3K) pathway, two central signaling cascades that regulate cell proliferation, differentiation, and survival[1][4][9][18][26]. Specifically, neudesin promotes the phosphorylation and activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2), which represent the central effectors of the classical MAPK pathway[1][4][9][18][26]. The phosphorylation of ERK1/2 by neudesin is sensitive to inhibition by pertussis toxin (PTX), a toxin that specifically inactivates inhibitory Gi/Go proteins by ADP-ribosylation of their α-subunits[1][4][18][26]. This PTX sensitivity indicates that neudesin activates the MAPK pathway through interaction with a Gi/Go-protein-coupled receptor (GPCR), likely a member of the inhibitory G-protein family[1][4][18][26].

In neural precursor cells, however, the mechanism of neudesin-mediated signaling diverges from that in mature neurons. Specifically, neudesin promotes phosphorylation of ERK, protein kinase A (PKA), and cAMP response element binding protein (CREB) in neural precursor cells, but this phosphorylation is not inhibited by pertussis toxin[1][4][9][15][25][26]. Additionally, neudesin increases intracellular cAMP levels in neural precursor cells, suggesting activation of a Gs-protein-coupled signaling pathway in these cells[1][4][9][15][25][26]. This distinction implies that neudesin interacts with different GPCR subtypes in mature neurons versus neural precursor cells, with mature neurons expressing predominantly Gi/Go-coupled receptors while neural precursor cells express primarily Gs-coupled receptors or receptors coupled to both G-protein families.

Beyond the MAPK and PI3K pathways, neudesin promotes the phosphorylation of Akt (also termed protein kinase B), a serine/threonine protein kinase that serves as a central regulator of cell survival and metabolic homeostasis[1][4][9][15][25][26]. The PI3K pathway is activated through recruitment and stimulation of phosphatidylinositol 3-kinase enzymes at the plasma membrane, leading to phosphorylation of phosphatidylinositol (4,5)-bisphosphate (PIP2) to generate phosphatidylinositol (3,4,5)-trisphosphate (PIP3)[1][4][9][15][25][26]. PIP3 serves as a membrane-docking site for proteins containing pleckstrin homology (PH) domains, including Akt and its upstream kinase PDK1 (phosphoinositide-dependent kinase 1)[1][4][9][15][25][26]. Phosphorylation and activation of Akt mediates many of the pro-survival effects of neudesin, including suppression of apoptotic pathways through inactivation of FoxO transcription factors and BH3-only proteins[1][4][9][15][25][26].

Notably, the precise identity of the neudesin receptor(s) remains unknown despite decades of investigation[1][4][9][15][19][25][26][33]. Although neudesin clearly activates signaling through G-protein-coupled receptors based on the PTX sensitivity and cAMP data, no specific GPCR has been definitively identified as a neudesin receptor[1][4][9][15][19][25][26]. This represents a significant gap in understanding neudesin's mechanism of action, as identification of the specific receptor would enable more targeted investigation of pathway selectivity and tissue-specific effects. The heme-binding domain of neudesin may itself participate in receptor recognition, as the neudesin-hemin complex shows substantially greater biological potency than neudesin alone, suggesting that heme binding may induce conformational changes that enhance receptor interaction or receptor binding affinity[7][36][44].

Neurotrophic Functions in Neural Development and Survival

The term "neurotrophic" describes proteins that promote the survival, differentiation, and growth of neurons and neural precursor cells, and neudesin exemplifies this category of biological activity. Neudesin exhibits robust neurotrophic activity in primary cultured mature neurons derived from embryonic mouse cerebral cortex, where recombinant neudesin significantly enhances neuronal survival by decreasing apoptotic cell death in a concentration-dependent manner[1][46][47][52]. In contrast, neudesin exhibits no mitogenic (proliferation-promoting) activity in primary cultured astrocytes, the glial cells that provide structural and metabolic support to neurons in the brain[1][46][47]. This selectivity indicates that neudesin is specifically a neurotrophic factor for neurons rather than a general growth factor for all cell types in the central nervous system. The fact that neudesin is secreted from neurons and acts on neurons or neighboring neurons, but not on astrocytes, suggests an autocrine or paracrine signaling mechanism within neuronal populations.

During the embryonic stage of brain development, when neural precursor cells are actively dividing and beginning to differentiate, neudesin promotes neurogenesis through two complementary mechanisms[1][4][46][48][49]. First, neudesin directly promotes the differentiation of neural precursor cells into mature neurons, as indicated by the increased expression of MAP-2 (microtubule-associated protein 2), a specific marker of differentiated neurons[1][4][46][48][49]. This neuronal differentiation is mediated through activation of the PI3K and PKA signaling pathways, as demonstrated by blocking experiments employing pathway-specific inhibitors[1][4][46][48][49]. Second, neudesin transiently promotes the proliferation of neural precursor cells early in the developmental process, which indirectly increases the number of neurons by expanding the population of cells capable of differentiating[1][4][46][48][49]. This proliferative effect is mediated through activation of the MAPK and PKA pathways but not through the PI3K pathway, representing a distinct mechanism from the differentiation-promoting effects[1][4][46][48][49]. The ability of neudesin to modulate both neural cell proliferation and differentiation in a temporal manner suggests that neudesin functions as a developmental switch that coordinates the transition from precursor proliferation to neuronal differentiation during brain development.

In neuroblastoma-derived cell lines such as Neuro2a cells, which represent undifferentiated neural precursor cells in culture, knockdown of endogenous neudesin using RNA interference markedly suppresses both cell survival and proliferation, indicating that neudesin is essential for maintaining the viability of undifferentiated neural cells[1][4][46][47]. Furthermore, the neudesin-hemin complex demonstrates substantially greater neuroprotective activity than neudesin alone in these cells, and remarkably, the neudesin-hemin complex, but neither neudesin nor hemin alone, significantly promotes both cell survival and proliferation in Neuro2a cells[1][4][46][47]. This synergistic effect of heme binding on neudesin activity suggests that neudesin may function as a sensor of cellular heme status and that heme binding represents an important mechanism for modulating neudesin's biological potency in response to heme availability.

Anxiety Circuitry, Dendritic Morphology, and Ventral Hippocampal Function

Emerging evidence indicates that neudesin plays a critical role in the maintenance of neural circuits that regulate anxiety-related behaviors, with this function being specifically localized to the ventral hippocampus and other limbic structures[17][52][55]. Neudesin knockout mice, generated through targeted disruption of the NENF gene, display a prominent and robust anxious-like behavioral phenotype, as measured by reduced time spent in the open arms of the elevated plus maze (a standard test in which anxious animals avoid open, exposed spaces), reduced time spent in the light zone of the light-dark box, and increased latency to eat in the novelty-suppressed feeding test (which measures the inhibition of feeding caused by the anxiety generated by unfamiliar environments)[17][52][55]. Importantly, neudesin knockout mice do not display depressive-like behavior or cognitive impairment, indicating that the anxiety-like phenotype results from selective alteration of anxiety circuitry rather than a global impairment of brain function[17][52][55].

The anatomical substrate for the anxiety phenotype in neudesin knockout mice involves specific alterations in dendritic morphology in brain regions critical for anxiety regulation[17][52][55]. Specifically, neudesin-deficient mice exhibit substantially shorter dendritic length in the dentate gyrus granule neurons of the ventral hippocampus compared to wild-type littermates, with measurements indicating approximately 37% reduction in total dendritic length (from 741.8 ± 32.8 μm in wild-type to 463.9 ± 83.3 μm in neudesin knockout animals)[17]. Sholl analysis, a quantitative technique for measuring dendritic branching complexity, revealed that neudesin knockout mice also have significantly fewer intersections of the dendritic tree at distances between 60 and 120 μm from the soma, indicating not just reduced total dendritic length but also reduced dendritic branching complexity[17]. These dendritic morphological alterations are region-specific and circuit-specific, as no differences in dendritic length or arborization were observed in hippocampal CA1 pyramidal neurons or in dorsal dentate gyrus neurons, suggesting that neudesin's role in dendritic development is specific to the ventral hippocampus[17][52][55]. Additionally, neudesin-deficient mice exhibit shorter dendrites in the anterior medial division of the bed nucleus of the stria terminalis (amBNST), another component of the anxiety circuitry, though no changes were observed in the lateral dorsal BNST or in the basolateral amygdala[17].

The anxiety-like phenotype observed in neudesin knockout mice is accompanied by altered monoaminergic neurotransmission in ventral hippocampal and related circuits[17][52][55]. Specifically, neudesin knockout mice demonstrate reduced dopamine levels in the ventral hippocampus, accompanied by elevated dopaminergic turnover as indicated by increased ratio of the dopamine metabolite homovanillic acid (HVA) to dopamine (HVA/DA)[17][52][55]. These neurochemical changes suggest that neudesin functions to support dopaminergic neurotransmission in the ventral hippocampus, and loss of neudesin leads to a compensatory increase in dopamine metabolism in response to reduced dopamine signaling. In the amygdala, there is a trend toward reduction in dopamine, DOPAC (another dopamine metabolite), and norepinephrine levels in neudesin knockout mice, though these changes did not reach statistical significance in all analyses[17][52][55]. These findings lead to the hypothesis that neudesin is a critical regulator of the anxiety circuitry through its role in maintaining dendritic arborization and supporting monoaminergic neurotransmission in the ventral hippocampus and related limbic structures.

Regulation of Energy Homeostasis and Appetite Control

In addition to its roles in neural development and anxiety regulation, neudesin plays a previously unrecognized function as a suppressor of energy expenditure and a potential negative regulator of sympathetic nervous system activity, making it a unique neurotrophic factor with metabolic effects opposite to most other known neurotrophic factors[3][4][20][23][40]. This discovery emerged from studies employing neudesin knockout mice, which were generated to elucidate the physiological functions of neudesin in peripheral tissues. Remarkably, neudesin knockout mice display profound resistance to high-fat diet (HFD)-induced obesity and associated metabolic dysfunction compared to wild-type littermates[3][4][20][23][40]. Specifically, when fed a high-fat diet, neudesin knockout mice maintain significantly lower body weight and exhibit substantially reduced adipocyte hypertrophy compared to wild-type mice consuming the same diet, indicating that neudesin is required for the development of diet-induced obesity[3][4][20][23][40].

The mechanism underlying obesity resistance in neudesin knockout mice is not reduced food intake, as neudesin knockout mice consume similar amounts of food to wild-type mice when fed a high-fat diet[4][20][23][43][47]. Instead, the obesity resistance results from increased energy expenditure mediated by elevated systemic sympathetic nervous system activity[3][4][20][23][40]. Measurements of oxygen consumption and heat production (thermogenesis) revealed that neudesin knockout mice fed a high-fat diet exhibit significantly elevated energy expenditure compared to wild-type controls[3][4][20][23][40]. This increased energy expenditure is accompanied by markedly elevated sympathetic activity in adipose tissue, as indicated by increased norepinephrine levels, increased expression of tyrosine hydroxylase (the rate-limiting enzyme in norepinephrine synthesis), and increased expression of β3-adrenergic receptors in adipose tissue[3][4][20][23][40]. Furthermore, examination of brown adipose tissue (BAT) in neudesin knockout mice revealed significantly elevated expression of uncoupling protein 1 (UCP1), carnitine palmitoyltransferase 1 (CPT1), PPARα, and PGC-1α, all markers of thermogenic capacity and fatty acid oxidation[3][4][20][23][40]. These findings indicate that neudesin normally acts to suppress sympathetic nervous system activity and thereby reduce energy expenditure.

The molecular mechanism by which neudesin suppresses sympathetic activity appears to involve direct effects on peripheral sympathetic neurons. Recombinant neudesin was shown to suppress the expression of tyrosine hydroxylase in differentiated PC12 cells, a neuronal cell line that exhibits sympathetic neuron-like properties and is commonly used to model sympathetic neuronal function[3][4][20][23][40]. This suppression of tyrosine hydroxylase expression in sympathetic neurons would be expected to reduce norepinephrine synthesis capacity and thereby suppress sympathetic neurotransmitter release in target tissues including adipose tissue[3][4][20][23][40]. Notably, the increased sympathetic activity in neudesin knockout mice fed a high-fat diet does not appear to be mediated by altered hypothalamic neuropeptide signaling, as expression levels of hypothalamic pro-opiomelanocortin (POMC), neuropeptide Y (NPY), agouti-related peptide (AGRP), brain-derived neurotrophic factor (BDNF), and corticotropin-releasing factor (CRF) were similar in neudesin knockout and wild-type mice[3][4][20][23][40]. This suggests that neudesin functions as a local signaling molecule in adipose tissue and sympathetic neurons to suppress sympathetic activity at the peripheral level rather than through central hypothalamic mechanisms.

Within the white adipose tissue (WAT), neudesin has also been shown to suppress adipogenesis (the differentiation of preadipocytes into mature adipocytes)[4][20][47]. Specifically, in cultured 3T3-L1 preadipocytes (a standard cell culture model of adipocyte differentiation), neudesin significantly suppresses adipogenic differentiation[4][20][47]. Conversely, knockdown of neudesin by RNA interference markedly promotes adipogenesis by reducing activation of the MAPK pathway, suggesting that neudesin is a negative regulator of adipogenesis that functions through MAPK pathway inhibition[4][20][47]. These findings indicate that neudesin acts as a negative regulator of adiposity at multiple levels: by suppressing sympathetic activity to reduce thermogenesis and energy expenditure, by directly suppressing adipogenesis to reduce the expansion of the adipocyte population, and by promoting lipolysis in existing white adipocytes through sympathetic stimulation.

Hypothalamic Regulation of Appetite and Food Intake

Beyond its roles in sympathetic regulation and adiposity, neudesin has been demonstrated to modulate appetite and food intake through hypothalamic mechanisms[1][4][19][56]. Hypothalamic neudesin mRNA expression is regulated by brain-derived neurotrophic factor (BDNF) signaling through the TrkB receptor, consistent with the known role of BDNF as an important regulator of appetite and energy balance[1][4][19][31][34][56]. Administration of recombinant neudesin directly into the lateral cerebral ventricle (intracerebroventricular injection) decreases food intake and reduces body weight in mice[1][4][19][56]. These anorexigenic (appetite-suppressing) effects of neudesin are mediated through activation of the melanocortin signaling system, specifically resulting in increased expression of pro-opiomelanocortin (POMC) mRNA and melanocortin 4 receptor (MC4R) mRNA in the hypothalamus[1][4][19][56]. The melanocortin system, including POMC neurons and MC4R signaling, is a central regulator of appetite and energy balance, with POMC derived α-melanocyte-stimulating hormone (α-MSH) acting as a potent appetite suppressant through activation of MC4R on downstream neurons in the paraventricular hypothalamus[31][59].

This anorexigenic function of neudesin appears to be specific to the hypothalamus and distinct from its roles in neuronal development and survival. In fact, there exists an apparent discrepancy between the pharmacological effects of administered recombinant neudesin (which decreases food intake and body weight) and the physiological phenotype of neudesin knockout mice (which do not display increased food intake when fed a high-fat diet)[4][20][23][43][47]. This discrepancy may reflect differences in the temporal and spatial localization of neudesin signaling, differences in the physiological contexts tested (fasting versus fed states, acute pharmacological administration versus chronic genetic knockout), or potentially different effects of neudesin on different hypothalamic neuronal populations. Further investigation will be required to reconcile these apparent contradictions and establish the precise role of neudesin in hypothalamic appetite regulation.

Expression in Peripheral Tissues and Non-Neural Functions

Although originally identified and characterized as a neurotrophic factor based on its neurotrophic activity in cultured neurons, neudesin is widely expressed in peripheral non-neuronal tissues in adult organisms, including white adipose tissue (WAT), brown adipose tissue (BAT), heart, lung, and kidney[1][3][4][19][20][37][40][46][47]. The expression of neudesin in these peripheral tissues is substantially lower than its expression in the central nervous system, suggesting that peripheral neudesin functions through local signaling mechanisms rather than systemic endocrine effects[3][4][20][40]. Notably, neudesin is not detected in the blood plasma, supporting the interpretation that neudesin functions as a local tissue factor rather than as a systemic hormone[3][4][20][40].

The presence of neudesin in adipose tissue is consistent with its roles in suppressing adipogenesis and sympathetic activity, as described above. In white adipose tissue, the expression of neudesin is significantly upregulated in wild-type mice fed a high-fat diet compared to mice fed normal chow, suggesting that neudesin expression may be induced as a compensatory response to obesity development[3][4][20][40]. However, this compensatory upregulation of neudesin expression appears to be insufficient to prevent diet-induced obesity in wild-type mice, possibly because the regulatory mechanisms governing neudesin-receptor signaling are limiting or because the magnitude of neudesin upregulation is inadequate to overcome the metabolic effects of a high-fat diet[3][4][20][40]. The discovery that neudesin suppresses energy expenditure through sympathetic inhibition appears counterintuitive given that most neurotrophic factors increase energy expenditure, leading to the important conceptual recognition that neudesin may represent a unique class of neurotrophic factors with metabolic functions opposite to the classical neurotrophic factors[3][4][20][40][43][47].

Role in Tumorigenesis and Overexpression in Human Cancers

Beyond its roles in neural development and energy metabolism, neudesin has been implicated in tumorigenesis and is overexpressed in multiple human cancer types, a finding that has positioned neudesin as a novel potential target for cancer therapeutics[4][13][16][20][38][41][47][57]. Neudesin was originally identified as GIG47 (growth-inhibited clone 47) using a differential display technique to discover genes that are altered during breast tumorigenesis, indicating that neudesin expression was discovered to be dysregulated in breast cancer[4][13][20][38][41][47]. Increased expression or overexpression of neudesin has been documented in tissues from multiple human cancers, including carcinomas of the breast, uterine cervix, colon, lung, and skin, as well as in malignant lymphoma and leukemia[4][13][16][20][38][41][47][57]. This widespread overexpression across diverse cancer types suggests that neudesin represents a common mechanism of tumorigenesis relevant to multiple cancer subtypes.

The mechanism through which neudesin promotes tumorigenesis has been investigated through ectopic expression experiments in cancer cell lines. Ectopic expression of neudesin in MCF7 breast cancer cells significantly increases cell invasiveness in vitro and enhances tumorigenicity in vivo in mouse xenograft models[4][13][20][38][41][47][57]. These tumorigenic effects are mediated through activation of the MAPK and PI3K signaling pathways, the same pathways through which neudesin promotes neuronal survival and proliferation[4][13][20][38][41][47][57]. The evidence that neudesin promotes both survival and invasiveness of cancer cells through these pathways suggests that neudesin may function as an oncogenic factor that drives cancer cell proliferation, survival, and metastatic potential.

Neudesin overexpression has been associated with DNA hypomethylation in multiple cancer types, suggesting an epigenetic mechanism for neudesin dysregulation in cancer[4][13][20][47][57]. Specifically, genome-wide methylation mapping has identified many activated gene promoters by DNA hypomethylation in hepatocellular carcinoma (HCC) clinical samples, and neudesin is among the genes found to be hypomethylated and upregulated in HCC[4][20][47][57]. This epigenetic dysregulation of neudesin through promoter hypomethylation appears to represent a common mechanism through which neudesin becomes overexpressed during cancer development. Importantly, loss of neudesin function through RNA interference has been shown to effectively and specifically inhibit cancer cell growth and invasive capacity in different cancer cell types, as well as to reduce tumor growth in explant models in mice and interfere with AKT, WNT, and MAPK signaling pathways[4][20][47][57]. These findings indicate that neudesin represents a potential therapeutic target for anti-cancer treatment, particularly in cancers characterized by neudesin overexpression.

Recent investigation has explored neudesin as a potential biomarker for astrocytic brain tumors, based on the observation that cerebrospinal fluid (CSF) neudesin concentrations are significantly elevated in astrocytic brain tumor patients compared to non-tumoral individuals[16]. Serum neudesin concentration is strongly correlated with CSF neudesin level in brain tumor patients, and the "Neudesin Quotient" (the ratio of CSF neudesin to serum neudesin, normalized for blood-brain barrier permeability) appears to be a more sensitive biomarker of astrocytic brain tumors than either CSF or serum neudesin concentrations alone[16]. Furthermore, serum neudesin concentration demonstrates gender-dependent variation in primary brain tumor patients, with larger effect sizes in female than male patients, suggesting that sex hormones may influence neudesin expression or metabolism[16]. These findings suggest that neudesin measurement in blood and CSF may provide diagnostic and prognostic utility in brain tumors, though further validation will be required before clinical implementation.

Comparison with Other MAPR Family Members

To fully appreciate neudesin's unique functions within the broader context of the MAPR family, it is instructive to compare its properties with other family members. PGRMC1, the first-identified MAPR family member and the prototype for the family, is a transmembrane protein primarily localized to the endoplasmic reticulum[9][26][29][47][57]. PGRMC1 binds heme rather than progesterone, despite its name, and plays roles in cell survival, damage resistance, lipid and drug metabolism in the liver, and neuroprotection in the brain[9][26][29][47][57]. PGRMC2 shares similar subcellular localization and some functions with PGRMC1 but exhibits distinct expression patterns and is also expressed in breast adenocarcinoma[9][26][47][57]. In contrast, neuferricin (also termed CYB5D2), another member of the MAPR family, is a secreted protein like neudesin but functions quite differently: neuferricin promotes neurogenesis in neural precursor cells yet suppresses cell survival in Neuro2a cells, an undifferentiated neural cell line where neudesin promotes both survival and proliferation[4][9][26][47][57].

These functional differences among MAPR family members reflect their distinct cellular localizations and evolutionary origins. The distinction between membrane-anchored PGRMC proteins and secreted MAPR proteins like neudesin and neuferricin appears to have profound functional consequences, with secreted MAR proteins operating as extracellular ligands for GPCRs while membrane-anchored proteins serve other roles in organellar function and intracellular signaling[9][26][47][57]. This distinction underscores the importance of precise classification and characterization of gene products and guards against assuming functional similarity based solely on the presence of conserved protein domains.

Structural Insights from NMR and Homology Modeling

The three-dimensional structure of neudesin has been determined through nuclear magnetic resonance (NMR) spectroscopy analysis of recombinant human neudesin, providing atomic-level resolution of the protein fold and the heme-binding domain architecture[9][26][43][47]. The NMR-derived structure indicates that neudesin comprises an antiparallel β-sandwich architecture with four α-helices and six β-strands arranged in the β1-α1-β2-β3-α2-β4-α3-α4-β5-β6 topology[9][26][43][47]. The heme-binding domain is formed within this overall structure, with the potential heme-binding hydrophobic pocket clearly visible between the α2 and α3 helices[9][15][26][43][47]. Homology modeling using the known three-dimensional structure of 1TOG, a hypothetical protein of unknown function with a cytochrome b5-like fold, confirmed the tertiary structure predictions and provided additional insight into the likely orientation of heme binding within neudesin[9][15][26][43][47]. The α2-β4-α3 topology that houses the heme-binding domain is conserved among MAPR family members, though the overall protein fold and flanking sequences diverge, particularly between the membrane-anchored PGRMC proteins and the secreted neudesin and neuferricin proteins[9][15][26][43][47].

The identification of critical tyrosine residues at positions 82 and 88 in the human neudesin sequence as essential for heme binding provides important functional insights into the mechanism of heme coordination within the protein[9][15][25][26][43][47]. Tyrosine residues are frequently employed as heme-binding ligands in heme-containing proteins, where they typically coordinate the iron atom through their phenolic hydroxyl groups, forming either monodentate or bidentate coordination bonds depending on the specific protein environment[9][15][25][26][43][47]. The requirement for both tyrosine residues suggests bidentate or cooperative iron coordination, providing high specificity and affinity for heme binding. The strict requirement for Fe(III)-protoporphyrin IX (hemin) over Fe(II)-protoporphyrin IX or protoporphyrin IX alone suggests that the iron oxidation state plays a critical role in either the thermodynamics of heme binding or the subsequent conformational changes required for receptor interaction[7][36][44].

Perspectives on Therapeutic Development and Future Directions

The multifunctional nature of neudesin and its roles in obesity, anxiety disorder, and tumorigenesis position it as an attractive target for therapeutic intervention in multiple clinical domains. The observation that neudesin knockout mice are resistant to diet-induced obesity and exhibit increased energy expenditure through enhanced sympathetic nervous system activity suggests that pharmacological antagonism of neudesin or its receptor could represent a novel approach to obesity treatment[3][4][20][23][40][43][47]. Such an antagonistic approach would differ from most current anti-obesity therapies, which generally aim to reduce appetite or increase satiety through hypothalamic melanocortin signaling; instead, neudesin antagonism would operate through peripheral sympathetic activation and enhanced energy expenditure. Conversely, the finding that neudesin knockout mice exhibit anxiety-like behaviors suggests that enhancing neudesin signaling or promoting neudesin expression might provide therapeutic benefit in anxiety disorders through mechanisms involving dendritic stabilization in ventral hippocampal circuits[17][52][55]. However, the apparent discrepancy between the effects of administered recombinant neudesin (appetite suppression, weight loss) and the phenotype of neudesin knockout mice (increased sympathetic activity, obesity resistance) suggests potential cell-type specific or context-dependent effects that will require careful investigation before therapeutic application.

The identification of the neudesin receptor(s) represents a critical outstanding challenge in neudesin biology. The evidence that neudesin activates signaling through G-protein-coupled receptors is compelling, based on PTX sensitivity and cAMP measurements, yet the specific GPCR(s) have not been definitively identified[1][4][9][15][19][25][26]. Identification of these receptors would enable rational drug design of receptor agonists or antagonists with targeted effects. Furthermore, the structural similarity between neudesin and other MAPR family members suggests that structure-based drug design approaches targeting the heme-binding domain might yield compounds with selective modulatory effects on neudesin signaling. The observation that heme binding substantially enhances neudesin activity raises the interesting possibility that modulating cellular heme availability or neudesin-heme complex formation could provide another avenue for therapeutic intervention[7][36][44].

In the cancer domain, the widespread overexpression of neudesin in human cancers and the demonstration that neudesin knockdown suppresses cancer cell growth and invasiveness suggest that antagonizing neudesin or its receptor could represent a novel therapeutic strategy, particularly for cancers characterized by neudesin overexpression such as breast cancer, hepatocellular carcinoma, and cervical carcinoma[4][13][16][20][38][41][47][57]. The fact that neudesin acts through the MAPK and PI3K pathways, which are already therapeutic targets in many cancers, suggests that neudesin antagonism might be combined with existing kinase inhibitors for synergistic therapeutic effects. However, the potential adverse effects of neudesin antagonism on neural development and anxiety circuitry would need to be carefully considered, suggesting that selective antagonism limited to peripheral tissues or cancer cells, if achievable, would be preferable to systemic neudesin antagonism.

Conclusion and Synthesis of Current Knowledge

Neudesin, the protein product of the NENF gene, represents a unique member of the cytochrome b5-related MAPR protein family with remarkable multifunctionality spanning neural development, energy homeostasis, anxiety circuitry maintenance, and tumorigenesis. The protein's defining feature is its conserved cytochrome b5-like heme/steroid-binding domain, which is essential for its biological activity and whose functional significance extends beyond classical heme proteins to include a role in receptor-mediated signaling. As a secreted protein, neudesin operates as an extracellular ligand for currently unidentified G-protein-coupled receptors, activating both Gi/Go-coupled and Gs-coupled signaling pathways through mechanisms that likely depend on heme binding for optimal receptor interaction. In the developing brain, neudesin functions as a classical neurotrophic factor, promoting neuronal differentiation and survival through activation of the PI3K and MAPK pathways. In the adult brain, particularly in the ventral hippocampus and related limbic structures, neudesin maintains the dendritic architecture and monoaminergic neurotransmission essential for anxiety circuitry function, with neudesin knockout mice displaying increased anxiety-like behaviors accompanied by reduced dendritic complexity in the ventral hippocampus. In peripheral tissues, particularly adipose tissue and sympathetic neurons, neudesin functions as a suppressor of energy expenditure through inhibition of sympathetic nervous system activity, representing a unique class of neurotrophic factor with metabolic effects opposite to classical neurotrophic factors. Within the hypothalamus, neudesin promotes appetite suppression through melanocortin signaling, though the relative contributions of central and peripheral neudesin to overall food intake remain to be fully elucidated. In cancer, neudesin is overexpressed in multiple human cancer types through mechanisms involving promoter hypomethylation and functions as an oncogenic factor promoting cancer cell survival, proliferation, and invasiveness through MAPK and PI3K pathway activation.

Despite significant recent advances in understanding neudesin's biology, important gaps remain, most notably the identity of the neudesin receptor(s), the structural basis for heme-dependent modulation of receptor interaction, and the precise mechanisms through which neudesin coordinates its diverse biological functions across neural and peripheral tissues. Future research employing structural biology, cell biology, and in vivo physiology approaches will undoubtedly provide additional insights into these unresolved questions and clarify neudesin's potential as a therapeutic target for metabolic, psychiatric, and oncologic disorders. The multifunctional nature of neudesin—its ability to regulate neural development, circuit maintenance, energy homeostasis, and cancer biology—makes it an exemplary system for understanding how individual proteins can be deployed across diverse biological contexts to control fundamental aspects of organismal physiology and disease.

Citations

1. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2013.00111/full
2. https://alphafold.ebi.ac.uk/entry/Q9UMX5
3. https://www.nature.com/articles/srep10049
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC4436896/
5. https://www.uniprot.org/uniprotkb/Q9UMX5/entry
6. https://onlinelibrary.wiley.com/doi/10.1002/jnr.20356
7. https://pubmed.ncbi.nlm.nih.gov/18056703/
8. https://www.nature.com/articles/s41392-024-01803-6
9. https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2015.00024/full
10. https://pmc.ncbi.nlm.nih.gov/articles/PMC2962481/
11. https://pubmed.ncbi.nlm.nih.gov/26042224/
12. https://pmc.ncbi.nlm.nih.gov/articles/PMC3586250/
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC6451205/
14. https://www.frontiersin.org/journals/behavioral-neuroscience/articles/10.3389/fnbeh.2013.00119/full
15. https://pmc.ncbi.nlm.nih.gov/articles/PMC2873040/
16. https://www.imrpress.com/journal/FBL/30/6/10.31083/FBL26581/htm
17. https://www.nature.com/articles/s41598-017-05423-9
18. https://pubmed.ncbi.nlm.nih.gov/16547973/
19. https://pmc.ncbi.nlm.nih.gov/articles/PMC7866220/
20. https://core.ac.uk/download/pdf/160455477.pdf
21. https://pmc.ncbi.nlm.nih.gov/articles/PMC2710100/
22. https://pubmed.ncbi.nlm.nih.gov/2568957/
23. https://academic.oup.com/endo/article/150/6/2646/2456110
24. https://onlinelibrary.wiley.com/doi/abs/10.1002/cne.902980209
25. https://pubmed.ncbi.nlm.nih.gov/22748190/
26. https://pmc.ncbi.nlm.nih.gov/articles/PMC6718311/
27. https://www.springermedicine.com/the-functional-and-structural-characterization-of-a-novel-oncoge/22384110
28. https://www.nature.com/articles/s41418-021-00814-y
29. https://pmc.ncbi.nlm.nih.gov/articles/PMC8732962/
30. https://pmc.ncbi.nlm.nih.gov/articles/PMC3544245/
31. https://pmc.ncbi.nlm.nih.gov/articles/PMC5808753/
32. https://e-century.us/files/ijcep/6/2/ijcep1211009.pdf
33. https://pmc.ncbi.nlm.nih.gov/articles/PMC10632371/
34. https://onlinelibrary.wiley.com/doi/abs/10.1002/jnr.20849
35. https://pmc.ncbi.nlm.nih.gov/articles/PMC4446192/
36. http://www.researchtrends.net/tia/article_pdf.asp?in=2&vn=14&tid=40&aid=3726